Literature DB >> 35550149

Multiscale study of the oral and gut environments in children with high- and low-threshold peanut allergy.

Lingdi Zhang1, Yoojin Chun1, Hsi-En Ho2, Zoe Arditi1, Tracy Lo3, Swathy Sajja3, Rebecca Rose4, Drew Jones4, Julie Wang3, Scott Sicherer3, Supinda Bunyavanich5.   

Abstract

BACKGROUND: The oral and gut microbiomes have each been associated with food allergy status. Within food allergy, they may also influence reaction thresholds.
OBJECTIVE: Our aim was to identify oral and gut microbiota associated with reaction thresholds in peanut allergy.
METHODS: A total of 59 children aged 4 to 14 years with suspected peanut allergy underwent double-blind, placebo-controlled food challenge to peanut. Those children who reacted at the 300-mg or higher dose of peanut were classified as high-threshold (HT), those who reacted to lower doses were classified as low-threshold (LT), and those children who did not react were classified as not peanut allergic (NPA). Saliva and stool samples collected before challenge underwent DNA isolation followed by 16S rRNA sequencing and short-chain fatty acid measurement.
RESULTS: The 59 participants included 38 HT children and 13 LT children. Saliva microbiome α-diversity (Shannon index) was higher in LT children (P = .017). We identified saliva and stool microbiota that distinguished HT children from LT children, including oral Veillonella nakazawae (amplicon sequence variant 1979), which was more abundant in the HT group than in the LT group (false discovery rate [FDR] = 0.025), and gut Bacteroides thetaiotaomicron (amplicon sequence variant 6829), which was less abundant in HT children than in LT children (FDR = 0.039). Comparison with NPA children revealed consistent ordinal trends between these discriminating species and reaction thresholds. Importantly, many of these threshold-associated species were also correlated with short-chain fatty acid levels at the respective body sites, including between oral V nakazawae and oral butyrate (r = 0.57; FDR = 0.049).
CONCLUSION: Findings from this multiscale study raise the possibility of microbial therapeutics to increase reaction thresholds in children with food allergy.
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Peanut allergy; gut; metabolomics; microbiome; oral; saliva; short-chain fatty acid; stool; threshold

Mesh:

Substances:

Year:  2022        PMID: 35550149      PMCID: PMC9463091          DOI: 10.1016/j.jaci.2022.04.026

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  24 in total

1.  Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-2010.

Authors:  Emily C McGowan; Corinne A Keet
Journal:  J Allergy Clin Immunol       Date:  2013-08-30       Impact factor: 10.793

2.  Early-life gut microbiome and egg allergy.

Authors:  M Fazlollahi; Y Chun; A Grishin; R A Wood; A W Burks; P Dawson; S M Jones; D Y M Leung; H A Sampson; S H Sicherer; S Bunyavanich
Journal:  Allergy       Date:  2018-03-15       Impact factor: 13.146

3.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

Review 4.  Role of the Microbiome in Food Allergy.

Authors:  Hsi-En Ho; Supinda Bunyavanich
Journal:  Curr Allergy Asthma Rep       Date:  2018-04-05       Impact factor: 4.806

5.  Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing.

Authors:  M Kalliomäki; P Kirjavainen; E Eerola; P Kero; S Salminen; E Isolauri
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

Review 6.  The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology.

Authors:  Yvonne J Huang; Benjamin J Marsland; Supinda Bunyavanich; Liam O'Mahony; Donald Y M Leung; Antonella Muraro; Thomas A Fleisher
Journal:  J Allergy Clin Immunol       Date:  2017-02-28       Impact factor: 10.793

Review 7.  Microbial Adjuncts for Food Allergen Immunotherapy.

Authors:  Hsi-En Ho; Supinda Bunyavanich
Journal:  Curr Allergy Asthma Rep       Date:  2019-03-22       Impact factor: 4.806

8.  Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy.

Authors:  Azza Abdel-Gadir; Emmanuel Stephen-Victor; Georg K Gerber; Magali Noval Rivas; Sen Wang; Hani Harb; Leighanne Wang; Ning Li; Elena Crestani; Sara Spielman; William Secor; Heather Biehl; Nicholas DiBenedetto; Xiaoxi Dong; Dale T Umetsu; Lynn Bry; Rima Rachid; Talal A Chatila
Journal:  Nat Med       Date:  2019-06-24       Impact factor: 53.440

9.  Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system.

Authors:  Keisuke Sato; Naoki Takahashi; Tamotsu Kato; Yumi Matsuda; Mai Yokoji; Miki Yamada; Takako Nakajima; Naoki Kondo; Naoto Endo; Reiko Yamamoto; Yuichiro Noiri; Hiroshi Ohno; Kazuhisa Yamazaki
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

10.  Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.

Authors:  Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.